GLP-1 Direct-Pay Pricing in 2026: LillyDirect, NovoCare and TrumpRx Compared

Direct-pay pricing means buying the medication straight from the drugmaker's own pharmacy instead of going through your insurance plan and a retail pharmacy. Eli Lilly launched LillyDirect and Novo Nordisk launched NovoCare Pharmacy to sell their obesity drugs at a fixed cash price to people whose insurance will not cover them.

The reason these programs exist comes down to a coverage gap. Fewer than half of commercial insurance plans covered GLP-1 medications for weight loss, and until 2026 Medicare was barred from covering obesity drugs at all. That left millions of people facing list prices above $1,000 a month. Many turned to compounded semaglutide, and when the FDA declared the shortage over and restricted compounding, the manufacturers needed a legitimate low-cost channel to keep those patients.

A third option arrived in 2026: TrumpRx, a federal direct-to-consumer platform created through an agreement between the White House, Eli Lilly and Novo Nordisk. It applies most-favored-nation pricing, meaning US cash prices are pegged closer to what other wealthy countries pay.

The practical effect for you is simple. You now have three routes to a brand-name GLP-1 that do not require prior authorization, an appeal letter, or a diagnosis code your insurer approves of. You need a valid prescription, and you pay cash. If you have already been through the insurance maze, you may find that [appealing a GLP-1 insurance denial](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) is no longer worth the effort compared to simply paying the direct price.

Zepbound (tirzepatide) through LillyDirect costs $299 per month for single-dose vials under the Zepbound Self Pay Journey Program, with multi-dose pens priced from $299 at the lowest dose up to $449 at higher strengths.

Here is what that structure means in practice. The vials require you to draw the dose yourself with a syringe, which some people find fiddly but which keeps the price flat regardless of strength. The pens are the familiar auto-injectors, and they price up as your dose escalates - so a person at 2.5 mg pays less than a person maintaining at 15 mg.

Mounjaro, which is the identical molecule approved for type 2 diabetes rather than obesity, is also sold through LillyDirect at self-pay rates. If you are unclear on why the same drug carries two names, our guide to [Mounjaro vs Zepbound](/blog/mounjaro-vs-zepbound-same-drug-different-label-2026) walks through the labeling difference.

A few practical notes. LillyDirect requires a valid prescription from your own clinician or from a telehealth provider in their network. The medication ships to your door, typically in two to five business days, in insulated packaging. You cannot combine the self-pay price with insurance - it is one or the other. And because this is a cash transaction, the spend generally counts as a qualified medical expense, so you can pay with [FSA or HSA dollars](/blog/glp1-fsa-hsa-pre-tax-dollars-save-on-weight-loss-2026) and effectively knock 20-30% off through the tax savings.

Wegovy (semaglutide) through NovoCare Pharmacy costs $149 to $349 per month depending on dose, and the oral semaglutide pill is priced in a similar $149 to $299 band.

Novo Nordisk moved aggressively on price after losing significant market share to tirzepatide. The lower end of that range - $149 - applies to starting doses and is the cheapest brand-name GLP-1 price the US market has seen. As you titrate up toward the 2.4 mg maintenance dose, the price climbs toward the upper end.

The oral pill deserves attention if needles are a barrier for you. Oral semaglutide is taken daily on an empty stomach with a small sip of water, and you have to wait 30 minutes before eating or drinking anything else. That routine is stricter than a weekly injection, and absorption is more variable. Our comparison of [oral versus injectable GLP-1s](/blog/oral-vs-injectable-glp1-which-is-right-for-you) covers the tradeoffs in detail.

One caution worth naming: price differences between Wegovy and Zepbound should not be your only deciding factor. SURMOUNT-5, the head-to-head trial published in 2025, found tirzepatide produced substantially greater average weight loss than semaglutide over 72 weeks - 19.7% of tirzepatide patients lost at least 30% of body weight versus 6.9% on semaglutide. If the cheaper drug works less well for you, the savings evaporate. Talk to your prescriber about which molecule suits your history, not just which line item is smaller.

TrumpRx is a federal direct-to-consumer website launched in 2026 that sells discounted medications, including GLP-1s, at cash prices starting around $350 per month with a stated glide path down to $250 over two years.

It came out of a November 2025 agreement between the administration, Eli Lilly and Novo Nordisk. In exchange for tariff relief and other concessions, the manufacturers agreed to most-favored-nation pricing on the platform and to expanded Medicare coverage. The same deal is what brought obesity drugs into Medicare Part D through a pilot program starting mid-2026, with Medicare paying roughly $245 per month and beneficiaries capped at a $50 monthly copay.

Whether TrumpRx is your best option depends on arithmetic, not politics. At launch, its headline prices were higher than what LillyDirect and NovoCare were already offering directly. The platform's advantage is breadth - it is meant to carry medications across many categories, not just obesity drugs - and its promised price reductions over time.

For most people reading this today, the manufacturer programs are cheaper. Check all three before you buy, because these prices have moved repeatedly and there is no reason to assume today's ranking holds next quarter.

If you are over 65, the Medicare change matters more than any cash price. Coverage now extends to eligible people with severe obesity or a weight-related condition. Our guide to [Medicare and GLP-1 coverage](/blog/does-medicare-cover-glp1-weight-loss-drugs-2026) explains the eligibility criteria and how to get your prescription processed under the new rules.

Sometimes yes, and more often than people expect. The comparison hinges on your specific plan design, not on general assumptions about insurance being better.

Run these four numbers before deciding. First, your actual copay or coinsurance for the specific drug - call the number on your insurance card and ask for the tier and cost-share, not a general answer. Second, your deductible status, because if you have a $3,000 deductible you have not met, you are paying full negotiated price until you do. Third, whether the plan requires prior authorization and what documentation it demands. Fourth, whether there is a step-therapy requirement forcing you to fail on a cheaper drug first.

A common scenario: a plan lists Wegovy on a specialty tier with 30% coinsurance against a negotiated price near $900. That is $270 a month, which is close to the cash price with none of the paperwork. Another common scenario: a plan covers it at a $25 copay, which no cash price will beat.

The group most likely to benefit from direct-pay is people whose plans exclude weight-loss drugs entirely, people on high-deductible plans early in the year, and people who have already been denied on appeal.

One more consideration. Compounded semaglutide is no longer the reliable discount it was - the regulatory landscape shifted substantially, as our piece on [compounded versus brand GLP-1s in 2026](/blog/compounded-vs-brand-glp1-what-changed-2026) explains. With brand prices now starting at $149, the argument for compounded versions has weakened considerably on both cost and safety grounds.

The single biggest price event on the horizon is orforglipron, Eli Lilly's oral GLP-1, which the company expected to reach FDA approval by March 2026. It is a small-molecule pill rather than a peptide, which means it can be manufactured at far higher volume and much lower cost than injectables.

Announced pricing targets put orforglipron in the $149 to $399 per month range, with future oral GLP-1s targeted at $149. If a pill delivers weight loss in the same neighborhood as injectable semaglutide at a third of the price and without cold-chain shipping, it resets the entire market. Our explainer on [orforglipron and the ATTAIN trial results](/blog/orforglipron-foundayo-oral-glp1-pill-attain-results) covers what the efficacy data actually showed.

Competition is the second force pushing prices down. Tirzepatide, semaglutide, CagriSema, MariTide, retatrutide and survodutide are all either approved or advancing through late-stage trials. More approved options mean more pricing pressure.

The third force is Medicare. Once a government payer covers a drug class at scale, the negotiated price becomes a reference point that ripples through commercial plans.

What this means for you practically: do not lock into a long prepaid supply at today's price if you can avoid it. Prices in this category have fallen every year since 2024, and there is no sign that trend has finished.